Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns
The drugmaker Regeneron Pharmaceuticals has agreed to buy the genetic testing firm 23andMe Holding for $256m through a bankruptcy auction, the companies announced on Monday.
Regeneron said it will comply with 23andMe’s privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer. The companies expect to close the deal in the third quarter.
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says
European journalists targeted with Paragon Solutions spyware, say researchers